Add-on Acquisition • Life Science

Sanofi Acquires Medley Indústria Farmacêutica

On April 9, 2009, Sanofi acquired life science company Medley Indústria Farmacêutica for 500M EUR

Acquisition Context

This is Sanofi’s 1st transaction in the Life Science sector.
This is Sanofi’s 11th largest (disclosed) transaction.
This is Sanofi’s 1st transaction in Brazil.

Explore All 3109 Add-on Acquisition Life Science Deals - Search the Database Free

M&A Deal Summary
Date	April 9, 2009
Target	Medley Indústria Farmacêutica
Sector	Life Science
Buyer(s)	Sanofi
Deal Type	Add-on Acquisition
Deal Value	500M EUR

Target Company

Medley Indústria Farmacêutica

Campinas, Brazil

Medley is the third largest pharmaceutical company and the number one generic company in Brazil. The company is the major generic player and the third largest pharmaceutical company in Brazil with a total 5.7% market share and a CAGR - Compound Annual Growth Rate - of 28% over the last 3 years (IMS MAT Feb. 09). The portfolio is composed of 127 products, out of which 17 of the top 20 generics products in the market.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Buyer Overview 1

Buyer

Sanofi

Paris, France

Category	Company
Founded	1994
Sector	Life Science
Employees	82,878
Revenue	44.3B EUR (2024)

DESCRIPTION

Sanofi is a French multinational pharmaceutical company. Sanofi was founded in 1994 and is based in Paris, France.

Deal Context for Buyer	#
Overall	2 of 32
Sector: Life Science	1 of 23
Type: Add-on Acquisition	1 of 25
Country: Brazil	1 of 1
Year: 2009	1 of 8
Size (of disclosed)	11 of 16

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2008-07-21	Symbion CP Holdings Pty Melbourne, Australia Symbion CP Holdings Pty Ltd. manufactures, markets and distributes nutraceuticals (vitamins & mineral supplements) and over the counter brands throughout Australia and New Zealand. Symbion Consumer has a strong portfolio of premium brands including Natures Own, Cenovis, Bio-organics, Golden Glow and Microgenics.	Buy	AU$560M

DATE

TARGET

DEAL TYPE

VALUE

2008-07-21

Symbion CP Holdings Pty

Melbourne, Australia

Symbion CP Holdings Pty Ltd. manufactures, markets and distributes nutraceuticals (vitamins & mineral supplements) and over the counter brands throughout Australia and New Zealand. Symbion Consumer has a strong portfolio of premium brands including Natures Own, Cenovis, Bio-organics, Golden Glow and Microgenics.

Buy

AU$560M

FOLLOWING DEAL

DATE	TARGET	DEAL TYPE	VALUE
2009-04-15	BiPar Sciences Brisbane, California, United States BiPar Sciences, Inc. is a biopharmaceutical company developing and commercializing potential new classes of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.	Buy	$500M

DATE

TARGET

DEAL TYPE

VALUE

2009-04-15

BiPar Sciences

Brisbane, California, United States

BiPar Sciences, Inc. is a biopharmaceutical company developing and commercializing potential new classes of tumor-selective drugs designed to meet the significant unmet needs of cancer patients.

Buy

$500M

Explore Related M&A Activity

Life Science M&A - Add-on Acquisition M&A Deals - Brazil M&A - 2009 M&A